Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil.

Marion OrtnerMarion StangeHeike SchneiderCharlotte SchröderKatharina BuergerClaudia MüllerFelix Müller-SarnowskiJanine Diehl-SchmidHans FörstlTimo GrimmerWerner Steimer

Published in: Drug design, development and therapy (2020)

Testing AChE-I serum concentration should be considered in patients without clinical response to treatment or those with severe side effects. Patients with donepezil drug levels outside the recommended range might additionally profit from CYP2D6 genotyping or treatment with an AChE-I independent of CYP metabolism.

Keyphrases

end stage renal disease
ejection fraction
prognostic factors
gene expression
peritoneal dialysis
genome wide
dna methylation
patient reported outcomes
patient reported